Algert Global LLC Purchases 16,292 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Algert Global LLC lifted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 59.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 43,592 shares of the company's stock after buying an additional 16,292 shares during the quarter. Algert Global LLC owned about 0.07% of Twist Bioscience worth $1,969,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. American International Group Inc. increased its stake in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company's stock worth $978,000 after purchasing an additional 213 shares during the period. PEAK6 Investments LLC boosted its position in shares of Twist Bioscience by 20.7% in the first quarter. PEAK6 Investments LLC now owns 14,000 shares of the company's stock valued at $480,000 after acquiring an additional 2,400 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Twist Bioscience by 7.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company's stock valued at $1,103,000 after acquiring an additional 2,292 shares in the last quarter. Bayesian Capital Management LP increased its position in Twist Bioscience by 42.7% during the first quarter. Bayesian Capital Management LP now owns 14,546 shares of the company's stock worth $499,000 after acquiring an additional 4,352 shares during the period. Finally, GAMMA Investing LLC raised its stake in Twist Bioscience by 1,896.8% in the 2nd quarter. GAMMA Investing LLC now owns 3,754 shares of the company's stock worth $185,000 after purchasing an additional 3,566 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TWST. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Scotiabank raised their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, November 19th. TD Cowen reaffirmed a "buy" rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $51.00.

Twist Bioscience Trading Up 4.3 %

NASDAQ:TWST traded up $1.98 on Thursday, hitting $48.32. The company had a trading volume of 691,981 shares, compared to its average volume of 950,291. The firm has a 50 day moving average of $43.78 and a two-hundred day moving average of $46.22. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -13.42 and a beta of 1.78. Twist Bioscience Co. has a 52 week low of $23.07 and a 52 week high of $60.90.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 1,057 shares of the firm's stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the transaction, the senior vice president now directly owns 121,013 shares in the company, valued at $5,029,300.28. This trade represents a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 1,507 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the sale, the insider now directly owns 91,163 shares of the company's stock, valued at $4,375,824. This represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.